hemocytometer after 5 days of incubation. D 10 values were calculated from survival curves of colony formation and represent the concentration of fatty acid that reduces the plating efficiency to 10%.
The ability of EPA and GLA to reduce the formation of colonies or cell number by the mdr and non-mdr cell lines is shown in Fig. 1 . By comparing the D 10 values obtained with both fatty acids, it is apparent that four of four of the tumorigenic mdr cell lines were two to five times more sensitive to EPA and GLA than their non-mdr tumongenic counterparts. Leukemia cell lines were less sensitive to these polyunsaturated fatty acids than the other cell lines.
Our results extend the initial findings using animal mdr cell lines and substantiate our hypothesis that certain mdr cancer cell variants are sensitive to EPA and GLA. Since effective anticancer concentrations of EPA and GLA can be achieved in vivo (8, 9) The authors wish to correct Table 8 . Eisenberger writes: "In the original publication, we reported our preliminary findings from a phase I study using a pharmacologically guided regimen with suramin. In Table 8 of that report, the toxic effects described for one of the studies were erroneous. The error involves the report by Myers et al. (7) in which the numbers expressing the incidence of grade 3 and 4 toxic effects are percentages and not actual numbers, as we reported. In the corrected Table 8 , all numbers represent percentages.
"While Table 8 notes the toxic effects of the three studies described, the reader should, in fact, be very cautious with regard to comparisons because of fundamental differences in study design. The study reported by Stein et al. (2) was a phase I trial, while Myers et al. (/) reported on a phase II trial using a pharmacologic end point (suramin plas- (2)] §Neurotoxicity was not classified according to sensory or motor. One case of a "post-viral GuillainBarre-like syndrome" was seen.
IITwo of three patients with fever had documented bacteremia (both were non-neutropemc) ma concentrations of 300 jig/mL). Our study was a phase I trial using welldefined and traditional clinical end points of dose-limiting toxicity or progression of disease. Thus, comparison of the incidence of toxic effects among these three studies may be flawed by the major differences in study design. The corrected Table 8 describes some of the similarities in the spectrum of toxicity in all three studies and suggests some possible qualitative differences, such as renal, coagulation, and ophthalmologic toxic effects. We cannot conclude from this table that one schedule is safer than another. We subsequently conducted a phase II trial with a pharmacologically based fixed schedule designed to maintain suramin plasma concentrations between 150 and 250 (ig/mL for a period of 78 days, essentially in the same manner as in cohort 2 of our original report [see also reference (3)], except that dose-limiting toxicity was not an end point. While toxic effects were qualitatively similar to those encountered in the patients treated at the same target plasma concentrations in our initial pharmacologically guided phase I trial, the incidence of grade 3 and 4 toxic effects was relatively low. We regret the error in our initial publication and wish to apologize to Myers et al. for the unintentional misrepresentation."
